神経損傷(Nerve Injury)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nerve Injury Overview 7
Therapeutics Development 8
Pipeline Products for Nerve Injury – Overview 8
Pipeline Products for Nerve Injury – Comparative Analysis 9
Nerve Injury – Therapeutics under Development by Companies 10
Nerve Injury – Therapeutics under Investigation by Universities/Institutes 11
Nerve Injury – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Nerve Injury – Products under Development by Companies 14
Nerve Injury – Products under Investigation by Universities/Institutes 15
Nerve Injury – Companies Involved in Therapeutics Development 16
Acorda Therapeutics, Inc. 16
Calico LLC 17
Convergence Pharmaceuticals Ltd. 18
F. Hoffmann-La Roche Ltd. 19
Kolon Life Science, Inc. 20
Medtronic, Inc. 21
Neuralstem, Inc. 22
Neurotune AG 23
Pfizer Inc. 24
Nerve Injury – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
3K3A-APC – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
cimaglermin alfa – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CLP-257 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CNV-1014802 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
KLS-Nst – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MDT-15 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NSI-566 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NT-1654 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Activate NAMPT for Neurological Disorders – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
WAY-258131 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Nerve Injury – Recent Pipeline Updates 49
Nerve Injury – Dormant Projects 58
Nerve Injury – Discontinued Products 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61